Umbralisib
Umbralisib is an experimental oral PI3K delta inhibitor. It also inhibits CK1 epsilon.
It has undergone clinical studies for chronic lymphocytic leukemia. Three year data was announced June 2016. It is in combination trials for various leukemias and lymphomas, such as mantle cell lymphoma and other lymphomas.
The drug has been granted the FDA's breakthrough therapy status for use in patients with marginal zone lymphoma, a type of cancer with no specifically approved therapies.
